changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact email@example.com
23 Jul 2019
BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere™ have been published by an international multidisciplinary working group¹. In addition, data from the Dosisphere phase II dosimetry trial supports MAA SPECT/CT based prospective personalised dosimetry².
16 Jul 2019
BTG International Asia Limited, a subsidiary of BTG plc (LSE: BTG) announced today that it has agreed to invest RMB 76million (approximately USD 11million) in the Chinese medical isotope diagnosis and treatment company Chengdu New Radiomedicine Technology Co., Ltd. (“CNRT”).
11 Jul 2019
BTG plc today highlighted the first publication of National Comprehensive Cancer Network (NCCN) pediatric acute lymphoblastic leukemia (ALL) guidelines including consideration of Voraxaze® (glucarpidase).
25 Jun 2019
Argentina now the second South American country to offer TheraSphere™ treatment for
liver cancer patients
Brazil to be the first South American country to offer TheraSphere® treatment for
liver cancer patients
29 Apr 2019
BTG plc today highlighted the VIEW VLU Registry interim study results, presented at the International Vein Congress in Miami, Florida. The interim findings confirm that Varithena® polidocanol injectable foam 1% shows promise in increasing the rate of wound healing.
BTG plc, the global healthcare company, today announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM).
18 Apr 2019
BTG plc (LSE: BTG), the global healthcare company, provides the following update for the 12 months ended 31 March 2019.
7 Mar 2019
BTG, the global healthcare company, exhibited the BTG Crossing Devices portfolio at the Chronic Total Occlusion (CTO) Summit in New York City from February 28 to March 1. Dr. Alexandre Avran of the Arnault Tzanck Institute in Nice, France, headlined the BTG exhibition at the summit this year, discussing his experience with the devices at a lunch symposium.
5 Mar 2019
BTG announced that research published today in PLOS ONE establishes the Patient-Specific Functional Scale (PSFS) as a valid, reliable, and clinically meaningful measure for assessing quality of life and functionality in snake envenomation studies.